dbSNP Short Genetic Variations
Welcome to the Reference SNP (rs) Report
All alleles are reported in the Forward orientation. Click on the Variant Details tab for details on Genomic Placement, Gene, and Amino Acid changes. HGVS names are in the HGVS tab.
Reference SNP (rs) Report
This page reports data for a single dbSNP Reference SNP variation (RefSNP or rs) from the new redesigned dbSNP build.
Top of the page reports a concise summary for the rs, with more specific details included in the corresponding tabs below.
All alleles are reported in the Forward orientation. Use the Genomic View to inspect the nucleotides flanking the variant, and its neighbors.
For more information see Help documentation.
rs2108622
Current Build 157
Released September 3, 2024
- Organism
- Homo sapiens
- Position
-
chr19:15879621 (GRCh38.p14) Help
The anchor position for this RefSNP. Includes all nucleotides potentially affected by this change, thus it can differ from HGVS, which is right-shifted. See here for details.
- Alleles
- C>A / C>G / C>T
- Variation Type
- SNV Single Nucleotide Variation
- Frequency
-
T=0.2935178 (411347/1401438, GnomAD_exomes)T=0.283397 (108918/384330, ALFA)T=0.226151 (59860/264690, TOPMED) (+ 25 more)
- Clinical Significance
- Reported in ClinVar
- Gene : Consequence
- CYP4F2 : Missense Variant
- Publications
- 202 citations
- Genomic View
- See rs on genome
ALFA Allele Frequency
The ALFA project provide aggregate allele frequency from dbGaP. More information is available on the project page including descriptions, data access, and terms of use.
Release Version: 20231103111315
| Population | Group | Sample Size | Ref Allele | Alt Allele | Ref HMOZ | Alt HMOZ | HTRZ | HWEP |
|---|---|---|---|---|---|---|---|---|
| Total | Global | 384330 | C=0.716603 | G=0.000000, T=0.283397 | 0.517883 | 0.084677 | 0.39744 | 32 |
| European | Sub | 321584 | C=0.706008 | G=0.000000, T=0.293992 | 0.500852 | 0.088835 | 0.410313 | 12 |
| African | Sub | 16650 | C=0.90973 | G=0.00000, T=0.09027 | 0.829429 | 0.00997 | 0.160601 | 3 |
| African Others | Sub | 594 | C=0.951 | G=0.000, T=0.049 | 0.905724 | 0.003367 | 0.090909 | 0 |
| African American | Sub | 16056 | C=0.90820 | G=0.00000, T=0.09180 | 0.826607 | 0.010214 | 0.163179 | 2 |
| Asian | Sub | 6902 | C=0.7273 | G=0.0000, T=0.2727 | 0.532599 | 0.077948 | 0.389452 | 1 |
| East Asian | Sub | 4908 | C=0.7319 | G=0.0000, T=0.2681 | 0.536267 | 0.072535 | 0.391198 | 0 |
| Other Asian | Sub | 1994 | C=0.7161 | G=0.0000, T=0.2839 | 0.523571 | 0.091274 | 0.385155 | 2 |
| Latin American 1 | Sub | 1512 | C=0.7606 | G=0.0000, T=0.2394 | 0.57672 | 0.055556 | 0.367725 | 0 |
| Latin American 2 | Sub | 8236 | C=0.7867 | G=0.0000, T=0.2133 | 0.618747 | 0.04541 | 0.335843 | 0 |
| South Asian | Sub | 5190 | C=0.6362 | G=0.0000, T=0.3638 | 0.410019 | 0.137572 | 0.452408 | 1 |
| Other | Sub | 24256 | C=0.71211 | G=0.00000, T=0.28789 | 0.510801 | 0.086577 | 0.402622 | 3 |
Frequency tab displays a table of the reference and alternate allele frequencies reported by various studies and populations. Table lines, where Population="Global" refer to the entire study population, whereas lines, where Group="Sub", refer to a study-specific population subgroupings (i.e. AFR, CAU, etc.), if available. Frequency for the alternate allele (Alt Allele) is a ratio of samples observed-to-total, where the numerator (observed samples) is the number of chromosomes in the study with the minor allele present (found in "Sample size", where Group="Sub"), and the denominator (total samples) is the total number of all chromosomes in the study for the variant (found in "Sample size", where Group="Study-wide" and Population="Global").
Download| Study | Population | Group | Sample Size | Ref Allele | Alt Allele |
|---|---|---|---|---|---|
| gnomAD v4 - Exomes | Global | Study-wide | 1401438 | C=0.7064822 | T=0.2935178 |
| gnomAD v4 - Exomes | European | Sub | 1165400 | C=0.7062562 | T=0.2937438 |
| gnomAD v4 - Exomes | South Asian | Sub | 86252 | C=0.61032 | T=0.38968 |
| gnomAD v4 - Exomes | American | Sub | 44720 | C=0.77138 | T=0.22862 |
| gnomAD v4 - Exomes | East Asian | Sub | 39690 | C=0.73056 | T=0.26944 |
| gnomAD v4 - Exomes | African | Sub | 33478 | C=0.90388 | T=0.09612 |
| gnomAD v4 - Exomes | Ashkenazi Jewish | Sub | 26136 | C=0.65243 | T=0.34757 |
| gnomAD v4 - Exomes | Middle Eastern | sub | 5762 | C=0.6204 | T=0.3796 |
| Allele Frequency Aggregator | Total | Global | 384330 | C=0.716603 | G=0.000000, T=0.283397 |
| Allele Frequency Aggregator | European | Sub | 321584 | C=0.706008 | G=0.000000, T=0.293992 |
| Allele Frequency Aggregator | Other | Sub | 24256 | C=0.71211 | G=0.00000, T=0.28789 |
| Allele Frequency Aggregator | African | Sub | 16650 | C=0.90973 | G=0.00000, T=0.09027 |
| Allele Frequency Aggregator | Latin American 2 | Sub | 8236 | C=0.7867 | G=0.0000, T=0.2133 |
| Allele Frequency Aggregator | Asian | Sub | 6902 | C=0.7273 | G=0.0000, T=0.2727 |
| Allele Frequency Aggregator | South Asian | Sub | 5190 | C=0.6362 | G=0.0000, T=0.3638 |
| Allele Frequency Aggregator | Latin American 1 | Sub | 1512 | C=0.7606 | G=0.0000, T=0.2394 |
| TopMed | Global | Study-wide | 264690 | C=0.773849 | T=0.226151 |
| gnomAD v4 - Genomes | Global | Study-wide | 149048 | C=0.771027 | T=0.228973 |
| gnomAD v4 - Genomes | European | Sub | 78532 | C=0.72547 | T=0.27453 |
| gnomAD v4 - Genomes | African | Sub | 41506 | C=0.90098 | T=0.09902 |
| gnomAD v4 - Genomes | American | Sub | 15280 | C=0.74202 | T=0.25798 |
| gnomAD v4 - Genomes | East Asian | Sub | 5158 | C=0.7540 | T=0.2460 |
| gnomAD v4 - Genomes | South Asian | Sub | 4810 | C=0.5990 | T=0.4010 |
| gnomAD v4 - Genomes | Ashkenazi Jewish | Sub | 3468 | C=0.6528 | T=0.3472 |
| gnomAD v4 - Genomes | Middle Eastern | sub | 294 | C=0.609 | T=0.391 |
| ExAC | Global | Study-wide | 121346 | C=0.727424 | T=0.272576 |
| ExAC | Europe | Sub | 73320 | C=0.72249 | T=0.27751 |
| ExAC | Asian | Sub | 25144 | C=0.64743 | T=0.35257 |
| ExAC | American | Sub | 11576 | C=0.77747 | T=0.22253 |
| ExAC | African | Sub | 10398 | C=0.90094 | T=0.09906 |
| ExAC | Other | Sub | 908 | C=0.716 | T=0.284 |
| 38KJPN | JAPANESE | Study-wide | 77430 | C=0.72084 | T=0.27916 |
| GO Exome Sequencing Project | Global | Study-wide | 13006 | C=0.77457 | T=0.22543 |
| GO Exome Sequencing Project | European American | Sub | 8600 | C=0.7088 | T=0.2912 |
| GO Exome Sequencing Project | African American | Sub | 4406 | C=0.9029 | T=0.0971 |
| Korean Genome Project 4K | KOREAN | Study-wide | 7230 | C=0.6813 | T=0.3187 |
| 1000Genomes_30X | Global | Study-wide | 6404 | C=0.7683 | T=0.2317 |
| 1000Genomes_30X | African | Sub | 1786 | C=0.9216 | T=0.0784 |
| 1000Genomes_30X | Europe | Sub | 1266 | C=0.7227 | T=0.2773 |
| 1000Genomes_30X | South Asian | Sub | 1202 | C=0.5824 | T=0.4176 |
| 1000Genomes_30X | East Asian | Sub | 1170 | C=0.7872 | T=0.2128 |
| 1000Genomes_30X | American | Sub | 980 | C=0.753 | T=0.247 |
| 1000Genomes | Global | Study-wide | 5008 | C=0.7632 | T=0.2368 |
| 1000Genomes | African | Sub | 1322 | C=0.9175 | T=0.0825 |
| 1000Genomes | East Asian | Sub | 1008 | C=0.7857 | T=0.2143 |
| 1000Genomes | Europe | Sub | 1006 | C=0.7097 | T=0.2903 |
| 1000Genomes | South Asian | Sub | 978 | C=0.587 | T=0.413 |
| 1000Genomes | American | Sub | 694 | C=0.762 | T=0.238 |
| The Avon Longitudinal Study of Parents and Children | PARENT AND CHILD COHORT | Study-wide | 3854 | C=0.6990 | T=0.3010 |
| UK 10K study - Twins | TWIN COHORT | Study-wide | 3708 | C=0.6917 | T=0.3083 |
| KOREAN population from KRGDB | KOREAN | Study-wide | 2930 | C=0.6570 | G=0.0000, T=0.3430 |
| HGDP-CEPH-db Supplement 1 | Global | Study-wide | 2084 | C=0.7174 | T=0.2826 |
| HGDP-CEPH-db Supplement 1 | Est_Asia | Sub | 470 | C=0.709 | T=0.291 |
| HGDP-CEPH-db Supplement 1 | Central_South_Asia | Sub | 414 | C=0.664 | T=0.336 |
| HGDP-CEPH-db Supplement 1 | Middle_Est | Sub | 350 | C=0.609 | T=0.391 |
| HGDP-CEPH-db Supplement 1 | Europe | Sub | 320 | C=0.706 | T=0.294 |
| HGDP-CEPH-db Supplement 1 | Africa | Sub | 242 | C=0.934 | T=0.066 |
| HGDP-CEPH-db Supplement 1 | America | Sub | 216 | C=0.894 | T=0.106 |
| HGDP-CEPH-db Supplement 1 | Oceania | Sub | 72 | C=0.40 | T=0.60 |
| HapMap | Global | Study-wide | 1886 | C=0.7853 | T=0.2147 |
| HapMap | American | Sub | 766 | C=0.744 | T=0.256 |
| HapMap | African | Sub | 692 | C=0.868 | T=0.132 |
| HapMap | Asian | Sub | 252 | C=0.774 | T=0.226 |
| HapMap | Europe | Sub | 176 | C=0.653 | T=0.347 |
| Genome-wide autozygosity in Daghestan | Global | Study-wide | 1124 | C=0.6486 | T=0.3514 |
| Genome-wide autozygosity in Daghestan | Daghestan | Sub | 624 | C=0.655 | T=0.345 |
| Genome-wide autozygosity in Daghestan | Near_East | Sub | 142 | C=0.620 | T=0.380 |
| Genome-wide autozygosity in Daghestan | Central Asia | Sub | 122 | C=0.705 | T=0.295 |
| Genome-wide autozygosity in Daghestan | Europe | Sub | 108 | C=0.731 | T=0.269 |
| Genome-wide autozygosity in Daghestan | South Asian | Sub | 92 | C=0.52 | T=0.48 |
| Genome-wide autozygosity in Daghestan | Caucasus | Sub | 36 | C=0.53 | T=0.47 |
| PharmGKB Aggregated | Global | Study-wide | 1044 | C=0.7222 | T=0.2778 |
| PharmGKB Aggregated | PA156060601 | Sub | 688 | C=0.705 | T=0.295 |
| PharmGKB Aggregated | PA149615754 | Sub | 356 | C=0.756 | T=0.244 |
| Genome of the Netherlands Release 5 | Genome of the Netherlands | Study-wide | 998 | C=0.742 | T=0.258 |
| Chileans | Chilean | Study-wide | 626 | C=0.827 | T=0.173 |
| A Vietnamese Genetic Variation Database | Global | Study-wide | 609 | C=0.768 | T=0.232 |
| Northern Sweden | ACPOP | Study-wide | 600 | C=0.750 | T=0.250 |
| Medical Genome Project healthy controls from Spanish population | Spanish controls | Study-wide | 534 | C=0.644 | T=0.356 |
| FINRISK | Finnish from FINRISK project | Study-wide | 304 | C=0.806 | T=0.194 |
| SGDP_PRJ | Global | Study-wide | 236 | C=0.398 | T=0.602 |
| Qatari | Global | Study-wide | 216 | C=0.606 | T=0.394 |
| The Danish reference pan genome | Danish | Study-wide | 40 | C=0.80 | T=0.20 |
| Siberian | Global | Study-wide | 28 | C=0.39 | T=0.61 |
| Ancient Sardinia genome-wide 1240k capture data generation and analysis | Global | Study-wide | 22 | C=0.73 | T=0.27 |
Help
Variant Details tab shows known variant placements on genomic sequences: chromosomes (NC_), RefSeqGene, pseudogenes or genomic regions (NG_), and in a separate table: on transcripts (NM_) and protein sequences (NP_). The corresponding transcript and protein locations are listed in adjacent lines, along with molecular consequences from Sequence Ontology. When no protein placement is available, only the transcript is listed. Column "Codon[Amino acid]" shows the actual base change in the format of "Reference > Alternate" allele, including the nucleotide codon change in transcripts, and the amino acid change in proteins, respectively, allowing for known ribosomal slippage sites. To view nucleotides adjacent to the variant use the Genomic View at the bottom of the page - zoom into the sequence until the nucleotides around the variant become visible.
Genomic Placements
| Sequence name | Change |
|---|---|
| GRCh38.p14 chr 19 | NC_000019.10:g.15879621C>A |
| GRCh38.p14 chr 19 | NC_000019.10:g.15879621C>G |
| GRCh38.p14 chr 19 | NC_000019.10:g.15879621C>T |
| GRCh37.p13 chr 19 | NC_000019.9:g.15990431C>A |
| GRCh37.p13 chr 19 | NC_000019.9:g.15990431C>G |
| GRCh37.p13 chr 19 | NC_000019.9:g.15990431C>T |
| CYP4F2 RefSeqGene | NG_007971.2:g.23454G>T |
| CYP4F2 RefSeqGene | NG_007971.2:g.23454G>C |
| CYP4F2 RefSeqGene | NG_007971.2:g.23454G>A |
Gene: CYP4F2, cytochrome P450 family 4 subfamily F member 2
(minus strand)
| Molecule type | Change | Amino acid[Codon] | SO Term |
|---|---|---|---|
| CYP4F2 transcript | NM_001082.5:c.1297G>T | V [GTG] > L [TTG] | Coding Sequence Variant |
| cytochrome P450 4F2 precursor | NP_001073.3:p.Val433Leu | V (Val) > L (Leu) | Missense Variant |
| CYP4F2 transcript | NM_001082.5:c.1297G>C | V [GTG] > L [CTG] | Coding Sequence Variant |
| cytochrome P450 4F2 precursor | NP_001073.3:p.Val433Leu | V (Val) > L (Leu) | Missense Variant |
| CYP4F2 transcript | NM_001082.5:c.1297G>A | V [GTG] > M [ATG] | Coding Sequence Variant |
| cytochrome P450 4F2 precursor | NP_001073.3:p.Val433Met | V (Val) > M (Met) | Missense Variant |
Help
Clinical Significance tab shows a list of clinical significance entries from ClinVar associated with the variation, per allele. Click on the RCV accession (i.e. RCV000001615.2) or Allele ID (i.e. 12274) to access full ClinVar report.
Allele: T (allele ID:
227800
)
| ClinVar Accession | Disease Names | Clinical Significance |
|---|---|---|
| RCV000211144.13 | acenocoumarol response - Dosage | Drug-Response |
| RCV000211318.11 | warfarin response - Dosage | Drug-Response |
| RCV001510827.13 | not provided | Benign |
| RCV003977584.1 | CYP4F2-related disorder | Likely-Benign |
Help
Aliases tab displays HGVS names representing the variant placements and allele changes on genomic, transcript and protein sequences, per allele. HGVS name is an expression for reporting sequence accession and version, sequence type, position, and allele change. The column "Note" can have two values: "diff" means that there is a difference between the reference allele (variation interval) at the placement reported in HGVS name and the reference alleles reported in other HGVS names, and "rev" means that the sequence of this variation interval at the placement reported in HGVS name is in reverse orientation to the sequence(s) of this variation in other HGVS names not labeled as "rev".
| Placement | C= | A | G | T |
|---|---|---|---|---|
| GRCh38.p14 chr 19 | NC_000019.10:g.15879621= | NC_000019.10:g.15879621C>A | NC_000019.10:g.15879621C>G | NC_000019.10:g.15879621C>T |
| GRCh37.p13 chr 19 | NC_000019.9:g.15990431= | NC_000019.9:g.15990431C>A | NC_000019.9:g.15990431C>G | NC_000019.9:g.15990431C>T |
| CYP4F2 RefSeqGene | NG_007971.2:g.23454= | NG_007971.2:g.23454G>T | NG_007971.2:g.23454G>C | NG_007971.2:g.23454G>A |
| CYP4F2 transcript | NM_001082.5:c.1297= | NM_001082.5:c.1297G>T | NM_001082.5:c.1297G>C | NM_001082.5:c.1297G>A |
| CYP4F2 transcript | NM_001082.4:c.1297= | NM_001082.4:c.1297G>T | NM_001082.4:c.1297G>C | NM_001082.4:c.1297G>A |
| CYP4F2 transcript | NM_001082.3:c.1297= | NM_001082.3:c.1297G>T | NM_001082.3:c.1297G>C | NM_001082.3:c.1297G>A |
| cytochrome P450 4F2 precursor | NP_001073.3:p.Val433= | NP_001073.3:p.Val433Leu | NP_001073.3:p.Val433Leu | NP_001073.3:p.Val433Met |
Help
Submissions tab displays variations originally submitted to dbSNP, now supporting this RefSNP cluster (rs). We display Submitter handle, Submission identifier, Date and Build number, when the submission appeared for the first time. Direct submissions to dbSNP have Submission ID in the form of an ss-prefixed number (ss#). Other supporting variations are listed in the table without ss#.
205 SubSNP,
32 Frequency,
4 ClinVar
submissions
| No | Submitter | Submission ID | Date (Build) |
|---|---|---|---|
| 1 | TSC-CSHL | ss3027906 | Jun 15, 2001 (96) |
| 2 | YUSUKE | ss3226797 | Sep 28, 2001 (100) |
| 3 | PGA-UW-FHCRC | ss4328382 | Mar 26, 2002 (103) |
| 4 | RIKENSNPRC | ss6311703 | Feb 20, 2003 (111) |
| 5 | ABI | ss44195107 | Mar 15, 2006 (126) |
| 6 | ILLUMINA | ss65726262 | Oct 15, 2006 (127) |
| 7 | ILLUMINA | ss66611224 | Nov 30, 2006 (127) |
| 8 | ILLUMINA | ss67224994 | Nov 30, 2006 (127) |
| 9 | ILLUMINA | ss67619762 | Nov 30, 2006 (127) |
| 10 | PERLEGEN | ss69224927 | May 17, 2007 (127) |
| 11 | ILLUMINA | ss70703289 | May 23, 2008 (130) |
| 12 | ILLUMINA | ss71269657 | May 17, 2007 (127) |
| 13 | AFFY | ss74806833 | Aug 16, 2007 (128) |
| 14 | ILLUMINA | ss75442178 | Dec 06, 2007 (129) |
| 15 | AFFY | ss76536285 | Dec 06, 2007 (129) |
| 16 | ILLUMINA | ss79114421 | Dec 14, 2007 (130) |
| 17 | KRIBB_YJKIM | ss83972881 | Dec 14, 2007 (130) |
| 18 | PHARMGKB_AB_DME | ss84157666 | Dec 14, 2007 (130) |
| 19 | HGSV | ss85348287 | Dec 14, 2007 (130) |
| 20 | CORNELL | ss86240312 | Mar 23, 2008 (129) |
| 21 | BCMHGSC_JDW | ss90914065 | Mar 24, 2008 (129) |
| 22 | PHARMGKB_PEAR | ss105109893 | Feb 04, 2009 (130) |
| 23 | SNP500CANCER | ss105439801 | Feb 04, 2009 (130) |
| 24 | ILLUMINA | ss121917510 | Dec 01, 2009 (131) |
| 25 | ENSEMBL | ss137570759 | Dec 01, 2009 (131) |
| 26 | ILLUMINA | ss153854667 | Dec 01, 2009 (131) |
| 27 | ILLUMINA | ss159359035 | Dec 01, 2009 (131) |
| 28 | SEATTLESEQ | ss159738914 | Dec 01, 2009 (131) |
| 29 | ILLUMINA | ss160502646 | Dec 01, 2009 (131) |
| 30 | ILLUMINA | ss171020280 | Jul 04, 2010 (132) |
| 31 | ILLUMINA | ss173118518 | Jul 04, 2010 (132) |
| 32 | BUSHMAN | ss203686935 | Jul 04, 2010 (132) |
| 33 | 1000GENOMES | ss228058788 | Jul 14, 2010 (132) |
| 34 | 1000GENOMES | ss237615436 | Jul 15, 2010 (132) |
| 35 | 1000GENOMES | ss243834738 | Jul 15, 2010 (132) |
| 36 | ILLUMINA | ss244287169 | Jul 04, 2010 (132) |
| 37 | BL | ss255522336 | May 09, 2011 (134) |
| 38 | GMI | ss283139012 | May 04, 2012 (137) |
| 39 | PJP | ss292218759 | May 09, 2011 (134) |
| 40 | NHLBI-ESP | ss342489430 | May 09, 2011 (134) |
| 41 | ILLUMINA | ss410919430 | Sep 17, 2011 (135) |
| 42 | ILLUMINA | ss480425465 | May 04, 2012 (137) |
| 43 | ILLUMINA | ss480439002 | May 04, 2012 (137) |
| 44 | ILLUMINA | ss481225176 | Sep 08, 2015 (146) |
| 45 | ILLUMINA | ss485010221 | May 04, 2012 (137) |
| 46 | 1000GENOMES | ss491152736 | May 04, 2012 (137) |
| 47 | EXOME_CHIP | ss491542365 | May 04, 2012 (137) |
| 48 | CLINSEQ_SNP | ss491761055 | May 04, 2012 (137) |
| 49 | ILLUMINA | ss537039506 | Sep 08, 2015 (146) |
| 50 | TISHKOFF | ss565879343 | Apr 25, 2013 (138) |
| 51 | SSMP | ss661735443 | Apr 25, 2013 (138) |
| 52 | ILLUMINA | ss779054974 | Sep 08, 2015 (146) |
| 53 | ILLUMINA | ss780742633 | Sep 08, 2015 (146) |
| 54 | ILLUMINA | ss782951413 | Sep 08, 2015 (146) |
| 55 | ILLUMINA | ss783420049 | Sep 08, 2015 (146) |
| 56 | ILLUMINA | ss783913657 | Sep 08, 2015 (146) |
| 57 | ILLUMINA | ss825444939 | Apr 01, 2015 (144) |
| 58 | ILLUMINA | ss832207359 | Sep 08, 2015 (146) |
| 59 | ILLUMINA | ss832870931 | Jul 13, 2019 (153) |
| 60 | ILLUMINA | ss834518003 | Sep 08, 2015 (146) |
| 61 | JMKIDD_LAB | ss974504841 | Aug 21, 2014 (142) |
| 62 | EVA-GONL | ss994129502 | Aug 21, 2014 (142) |
| 63 | JMKIDD_LAB | ss1067586018 | Aug 21, 2014 (142) |
| 64 | JMKIDD_LAB | ss1081785072 | Aug 21, 2014 (142) |
| 65 | 1000GENOMES | ss1362514162 | Aug 21, 2014 (142) |
| 66 | HAMMER_LAB | ss1397755369 | Sep 08, 2015 (146) |
| 67 | DDI | ss1428348463 | Apr 01, 2015 (144) |
| 68 | EVA_GENOME_DK | ss1578572008 | Apr 01, 2015 (144) |
| 69 | EVA_FINRISK | ss1584115376 | Apr 01, 2015 (144) |
| 70 | EVA_UK10K_ALSPAC | ss1637641197 | Apr 01, 2015 (144) |
| 71 | EVA_UK10K_TWINSUK | ss1680635230 | Apr 01, 2015 (144) |
| 72 | EVA_EXAC | ss1693442951 | Apr 01, 2015 (144) |
| 73 | EVA_DECODE | ss1698188832 | Apr 01, 2015 (144) |
| 74 | EVA_MGP | ss1711502672 | Apr 01, 2015 (144) |
| 75 | EVA_SVP | ss1713653204 | Apr 01, 2015 (144) |
| 76 | ILLUMINA | ss1752275577 | Sep 08, 2015 (146) |
| 77 | ILLUMINA | ss1752275578 | Sep 08, 2015 (146) |
| 78 | ILLUMINA | ss1917934170 | Feb 12, 2016 (147) |
| 79 | WEILL_CORNELL_DGM | ss1937615400 | Feb 12, 2016 (147) |
| 80 | ILLUMINA | ss1946529959 | Feb 12, 2016 (147) |
| 81 | ILLUMINA | ss1946529960 | Feb 12, 2016 (147) |
| 82 | ILLUMINA | ss1959847007 | Feb 12, 2016 (147) |
| 83 | ILLUMINA | ss1959847008 | Feb 12, 2016 (147) |
| 84 | JJLAB | ss2029580494 | Sep 14, 2016 (149) |
| 85 | ILLUMINA | ss2094803732 | Dec 20, 2016 (150) |
| 86 | ILLUMINA | ss2095083663 | Dec 20, 2016 (150) |
| 87 | USC_VALOUEV | ss2158107219 | Dec 20, 2016 (150) |
| 88 | HUMAN_LONGEVITY | ss2224611685 | Dec 20, 2016 (150) |
| 89 | SYSTEMSBIOZJU | ss2629289432 | Nov 08, 2017 (151) |
| 90 | ILLUMINA | ss2633522783 | Nov 08, 2017 (151) |
| 91 | ILLUMINA | ss2633522784 | Nov 08, 2017 (151) |
| 92 | GRF | ss2702712140 | Nov 08, 2017 (151) |
| 93 | ILLUMINA | ss2710662134 | Nov 08, 2017 (151) |
| 94 | GNOMAD | ss2743745355 | Nov 08, 2017 (151) |
| 95 | GNOMAD | ss2750107596 | Nov 08, 2017 (151) |
| 96 | GNOMAD | ss2960943634 | Nov 08, 2017 (151) |
| 97 | AFFY | ss2985135059 | Nov 08, 2017 (151) |
| 98 | AFFY | ss2985767790 | Nov 08, 2017 (151) |
| 99 | SWEGEN | ss3017172662 | Nov 08, 2017 (151) |
| 100 | ILLUMINA | ss3021887575 | Nov 08, 2017 (151) |
| 101 | ILLUMINA | ss3021887576 | Nov 08, 2017 (151) |
| 102 | BIOINF_KMB_FNS_UNIBA | ss3028622882 | Nov 08, 2017 (151) |
| 103 | CSHL | ss3352218066 | Nov 08, 2017 (151) |
| 104 | ILLUMINA | ss3625738143 | Oct 12, 2018 (152) |
| 105 | ILLUMINA | ss3627899123 | Oct 12, 2018 (152) |
| 106 | ILLUMINA | ss3627899124 | Oct 12, 2018 (152) |
| 107 | ILLUMINA | ss3631495548 | Oct 12, 2018 (152) |
| 108 | ILLUMINA | ss3633175836 | Oct 12, 2018 (152) |
| 109 | ILLUMINA | ss3633885787 | Oct 12, 2018 (152) |
| 110 | ILLUMINA | ss3634727222 | Oct 12, 2018 (152) |
| 111 | ILLUMINA | ss3634727223 | Oct 12, 2018 (152) |
| 112 | ILLUMINA | ss3635572733 | Oct 12, 2018 (152) |
| 113 | ILLUMINA | ss3636415383 | Oct 12, 2018 (152) |
| 114 | ILLUMINA | ss3637324437 | Oct 12, 2018 (152) |
| 115 | ILLUMINA | ss3638218705 | Oct 12, 2018 (152) |
| 116 | ILLUMINA | ss3639116691 | Oct 12, 2018 (152) |
| 117 | ILLUMINA | ss3639568643 | Oct 12, 2018 (152) |
| 118 | ILLUMINA | ss3640434530 | Oct 12, 2018 (152) |
| 119 | ILLUMINA | ss3640434531 | Oct 12, 2018 (152) |
| 120 | ILLUMINA | ss3643192430 | Oct 12, 2018 (152) |
| 121 | ILLUMINA | ss3644718538 | Oct 12, 2018 (152) |
| 122 | ILLUMINA | ss3644718539 | Oct 12, 2018 (152) |
| 123 | OMUKHERJEE_ADBS | ss3646531682 | Oct 12, 2018 (152) |
| 124 | ILLUMINA | ss3652312368 | Oct 12, 2018 (152) |
| 125 | ILLUMINA | ss3652312369 | Oct 12, 2018 (152) |
| 126 | ILLUMINA | ss3653906941 | Oct 12, 2018 (152) |
| 127 | EVA_DECODE | ss3702432955 | Jul 13, 2019 (153) |
| 128 | ILLUMINA | ss3725714091 | Jul 13, 2019 (153) |
| 129 | ACPOP | ss3742892187 | Jul 13, 2019 (153) |
| 130 | ILLUMINA | ss3744164499 | Jul 13, 2019 (153) |
| 131 | ILLUMINA | ss3744461242 | Jul 13, 2019 (153) |
| 132 | ILLUMINA | ss3745027261 | Jul 13, 2019 (153) |
| 133 | ILLUMINA | ss3745027262 | Jul 13, 2019 (153) |
| 134 | EVA | ss3755860511 | Jul 13, 2019 (153) |
| 135 | ILLUMINA | ss3772524491 | Jul 13, 2019 (153) |
| 136 | ILLUMINA | ss3772524492 | Jul 13, 2019 (153) |
| 137 | PACBIO | ss3788480524 | Jul 13, 2019 (153) |
| 138 | PACBIO | ss3793398333 | Jul 13, 2019 (153) |
| 139 | PACBIO | ss3798285029 | Jul 13, 2019 (153) |
| 140 | KHV_HUMAN_GENOMES | ss3821115232 | Jul 13, 2019 (153) |
| 141 | EVA | ss3825255612 | Apr 27, 2020 (154) |
| 142 | EVA | ss3825929459 | Apr 27, 2020 (154) |
| 143 | EVA | ss3835374449 | Apr 27, 2020 (154) |
| 144 | HGDP | ss3847595876 | Apr 27, 2020 (154) |
| 145 | SGDP_PRJ | ss3887857510 | Apr 27, 2020 (154) |
| 146 | KRGDB | ss3937850906 | Apr 27, 2020 (154) |
| 147 | FSA-LAB | ss3984147272 | Apr 27, 2021 (155) |
| 148 | EVA | ss3984450438 | Apr 27, 2021 (155) |
| 149 | EVA | ss3984450439 | Apr 27, 2021 (155) |
| 150 | EVA | ss3984739553 | Apr 27, 2021 (155) |
| 151 | EVA | ss3984739554 | Apr 27, 2021 (155) |
| 152 | EVA | ss3985847641 | Apr 27, 2021 (155) |
| 153 | EVA | ss3986079692 | Apr 27, 2021 (155) |
| 154 | EVA | ss3986784708 | Apr 27, 2021 (155) |
| 155 | EVA | ss4017817683 | Apr 27, 2021 (155) |
| 156 | TOMMO_GENOMICS | ss6181586799 | Nov 02, 2024 (157) |
| 157 | EVA | ss6277626287 | Nov 02, 2024 (157) |
| 158 | EVA | ss6319289178 | Nov 02, 2024 (157) |
| 159 | EVA | ss6322041873 | Nov 02, 2024 (157) |
| 160 | EVA | ss6322625823 | Nov 02, 2024 (157) |
| 161 | EVA | ss6333471957 | Nov 02, 2024 (157) |
| 162 | YEGNASUBRAMANIAN_LAB | ss6347819461 | Nov 02, 2024 (157) |
| 163 | EVA | ss6349958736 | Nov 02, 2024 (157) |
| 164 | KOGIC | ss6398182038 | Nov 02, 2024 (157) |
| 165 | EVA | ss6404205566 | Nov 02, 2024 (157) |
| 166 | EVA | ss6404517043 | Nov 02, 2024 (157) |
| 167 | EVA | ss6404694922 | Nov 02, 2024 (157) |
| 168 | GNOMAD | ss6465265018 | Nov 02, 2024 (157) |
| 169 | TOPMED | ss8069344314 | Nov 02, 2024 (157) |
| 170 | TOMMO_GENOMICS | ss8226956354 | Nov 02, 2024 (157) |
| 171 | EVA | ss8236957552 | Nov 02, 2024 (157) |
| 172 | EVA | ss8237594473 | Nov 02, 2024 (157) |
| 173 | EVA | ss8237594474 | Nov 02, 2024 (157) |
| 174 | EVA | ss8237672023 | Nov 02, 2024 (157) |
| 175 | 1000G_HIGH_COVERAGE | ss8306651198 | Nov 02, 2024 (157) |
| 176 | TRAN_CS_UWATERLOO | ss8314452463 | Nov 02, 2024 (157) |
| 177 | EVA | ss8315964746 | Nov 02, 2024 (157) |
| 178 | EVA | ss8433821733 | Nov 02, 2024 (157) |
| 179 | HUGCELL_USP | ss8499258079 | Nov 02, 2024 (157) |
| 180 | EVA | ss8512049094 | Nov 02, 2024 (157) |
| 181 | EVA | ss8512473939 | Nov 02, 2024 (157) |
| 182 | 1000G_HIGH_COVERAGE | ss8612109867 | Nov 02, 2024 (157) |
| 183 | EVA | ss8623976825 | Nov 02, 2024 (157) |
| 184 | EVA | ss8624087144 | Nov 02, 2024 (157) |
| 185 | SANFORD_IMAGENETICS | ss8624425198 | Nov 02, 2024 (157) |
| 186 | SANFORD_IMAGENETICS | ss8662060918 | Nov 02, 2024 (157) |
| 187 | TOMMO_GENOMICS | ss8785311404 | Nov 02, 2024 (157) |
| 188 | EVA | ss8799404773 | Nov 02, 2024 (157) |
| 189 | EVA | ss8800005032 | Nov 02, 2024 (157) |
| 190 | EVA | ss8800220227 | Nov 02, 2024 (157) |
| 191 | YY_MCH | ss8817445982 | Nov 02, 2024 (157) |
| 192 | EVA | ss8840315230 | Nov 02, 2024 (157) |
| 193 | EVA | ss8847494450 | Nov 02, 2024 (157) |
| 194 | EVA | ss8847837936 | Nov 02, 2024 (157) |
| 195 | EVA | ss8848484986 | Nov 02, 2024 (157) |
| 196 | EVA | ss8852221536 | Nov 02, 2024 (157) |
| 197 | EVA | ss8927459668 | Nov 02, 2024 (157) |
| 198 | EVA | ss8953479395 | Nov 02, 2024 (157) |
| 199 | EVA | ss8979541434 | Nov 02, 2024 (157) |
| 200 | EVA | ss8981036615 | Nov 02, 2024 (157) |
| 201 | EVA | ss8981836598 | Nov 02, 2024 (157) |
| 202 | EVA | ss8981836599 | Nov 02, 2024 (157) |
| 203 | EVA | ss8982058198 | Nov 02, 2024 (157) |
| 204 | EVA | ss8982306058 | Nov 02, 2024 (157) |
| 205 | GNOMAD | ss10046278913 | Nov 02, 2024 (157) |
| 206 | 1000Genomes | NC_000019.9 - 15990431 | Oct 12, 2018 (152) |
| 207 | 1000Genomes_30X | NC_000019.10 - 15879621 | Nov 02, 2024 (157) |
| 208 | The Avon Longitudinal Study of Parents and Children | NC_000019.9 - 15990431 | Oct 12, 2018 (152) |
| 209 | Chileans | NC_000019.9 - 15990431 | Apr 27, 2020 (154) |
| 210 | Genome-wide autozygosity in Daghestan | NC_000019.8 - 15851431 | Apr 27, 2020 (154) |
| 211 | ExAC | NC_000019.9 - 15990431 | Oct 12, 2018 (152) |
| 212 | FINRISK | NC_000019.9 - 15990431 | Apr 27, 2020 (154) |
| 213 | The Danish reference pan genome | NC_000019.9 - 15990431 | Apr 27, 2020 (154) |
| 214 | gnomAD v4 - Exomes | NC_000019.10 - 15879621 | Nov 02, 2024 (157) |
| 215 | gnomAD v4 - Genomes | NC_000019.10 - 15879621 | Nov 02, 2024 (157) |
| 216 | GO Exome Sequencing Project | NC_000019.9 - 15990431 | Oct 12, 2018 (152) |
| 217 | Genome of the Netherlands Release 5 | NC_000019.9 - 15990431 | Apr 27, 2020 (154) |
| 218 | HGDP-CEPH-db Supplement 1 | NC_000019.8 - 15851431 | Apr 27, 2020 (154) |
| 219 | HapMap | NC_000019.10 - 15879621 | Apr 27, 2020 (154) |
| 220 | KOREAN population from KRGDB | NC_000019.9 - 15990431 | Apr 27, 2020 (154) |
| 221 | Korean Genome Project 4K | NC_000019.10 - 15879621 | Nov 02, 2024 (157) |
| 222 | Medical Genome Project healthy controls from Spanish population | NC_000019.9 - 15990431 | Apr 27, 2020 (154) |
| 223 | Northern Sweden | NC_000019.9 - 15990431 | Jul 13, 2019 (153) |
| 224 | Ancient Sardinia genome-wide 1240k capture data generation and analysis | NC_000019.9 - 15990431 | Apr 27, 2021 (155) |
| 225 |
CNV burdens in cranial meningiomas
Submission ignored due to conflicting rows: |
- | Apr 27, 2021 (155) |
| 226 |
CNV burdens in cranial meningiomas
Submission ignored due to conflicting rows: |
- | Apr 27, 2021 (155) |
| 227 |
MxGDAR/Encodat-PGx
Submission ignored due to conflicting rows: |
- | Apr 27, 2021 (155) |
| 228 |
MxGDAR/Encodat-PGx
Submission ignored due to conflicting rows: |
- | Apr 27, 2021 (155) |
| 229 | PharmGKB Aggregated | NC_000019.10 - 15879621 | Apr 27, 2020 (154) |
| 230 | Qatari | NC_000019.9 - 15990431 | Apr 27, 2020 (154) |
| 231 | SGDP_PRJ | NC_000019.9 - 15990431 | Apr 27, 2020 (154) |
| 232 | Siberian | NC_000019.9 - 15990431 | Apr 27, 2020 (154) |
| 233 | 38KJPN | NC_000019.10 - 15879621 | Nov 02, 2024 (157) |
| 234 | TopMed | NC_000019.10 - 15879621 | Apr 27, 2021 (155) |
| 235 | UK 10K study - Twins | NC_000019.9 - 15990431 | Oct 12, 2018 (152) |
| 236 | A Vietnamese Genetic Variation Database | NC_000019.9 - 15990431 | Jul 13, 2019 (153) |
| 237 | ALFA | NC_000019.10 - 15879621 | Nov 02, 2024 (157) |
| 238 | ClinVar | RCV000211144.13 | Nov 02, 2024 (157) |
| 239 | ClinVar | RCV000211318.11 | Nov 02, 2024 (157) |
| 240 | ClinVar | RCV001510827.13 | Nov 02, 2024 (157) |
| 241 | ClinVar | RCV003977584.1 | Nov 02, 2024 (157) |
Help
History tab displays RefSNPs (Associated ID) from previous builds (Build) that now support the current RefSNP, and the dates, when the history was updated for each Associated ID (History Updated).
| Associated ID | History Updated (Build) |
|---|---|
| rs52819608 | Sep 21, 2007 (128) |
| rs57319528 | May 23, 2008 (130) |
| rs116975254 | Aug 16, 2010 (132) |
Added to this RefSNP Cluster:
| Submission IDs | Observation SPDI | Canonical SPDI | Source RSIDs |
|---|---|---|---|
| ss8512473939 | NC_000019.9:15990430:C:A | NC_000019.10:15879620:C:A | (self) |
| 45028300, ss3937850906, ss8512473939 | NC_000019.9:15990430:C:G | NC_000019.10:15879620:C:G | (self) |
| 10702975169 | NC_000019.10:15879620:C:G | NC_000019.10:15879620:C:G | (self) |
| 224955, 273768, ss76536285, ss85348287, ss90914065, ss203686935, ss255522336, ss283139012, ss292218759, ss480425465, ss491761055, ss825444939, ss1397755369, ss1698188832, ss1713653204, ss2710662134, ss3639116691, ss3639568643, ss3643192430, ss3847595876 | NC_000019.8:15851430:C:T | NC_000019.10:15879620:C:T | (self) |
| 75897960, 42046791, 202852, 3935934, 111837, 4757103, 1712593, 18731958, 45028300, 618432, 16177052, 1073568, 19657322, 39874490, 10623573, 42046791, 9292996, ss228058788, ss237615436, ss243834738, ss342489430, ss480439002, ss481225176, ss485010221, ss491152736, ss491542365, ss537039506, ss565879343, ss661735443, ss779054974, ss780742633, ss782951413, ss783420049, ss783913657, ss832207359, ss832870931, ss834518003, ss974504841, ss994129502, ss1067586018, ss1081785072, ss1362514162, ss1428348463, ss1578572008, ss1584115376, ss1637641197, ss1680635230, ss1693442951, ss1711502672, ss1752275577, ss1752275578, ss1917934170, ss1937615400, ss1946529959, ss1946529960, ss1959847007, ss1959847008, ss2029580494, ss2094803732, ss2095083663, ss2158107219, ss2629289432, ss2633522783, ss2633522784, ss2702712140, ss2743745355, ss2750107596, ss2960943634, ss2985135059, ss2985767790, ss3017172662, ss3021887575, ss3021887576, ss3352218066, ss3625738143, ss3627899123, ss3627899124, ss3631495548, ss3633175836, ss3633885787, ss3634727222, ss3634727223, ss3635572733, ss3636415383, ss3637324437, ss3638218705, ss3640434530, ss3640434531, ss3644718538, ss3644718539, ss3646531682, ss3652312368, ss3652312369, ss3653906941, ss3742892187, ss3744164499, ss3744461242, ss3745027261, ss3745027262, ss3755860511, ss3772524491, ss3772524492, ss3788480524, ss3793398333, ss3798285029, ss3825255612, ss3825929459, ss3835374449, ss3887857510, ss3937850906, ss3984147272, ss3984450438, ss3984450439, ss3984739553, ss3984739554, ss3985847641, ss3986079692, ss3986784708, ss4017817683, ss6277626287, ss6319289178, ss6322625823, ss6333471957, ss6347819461, ss6349958736, ss6404517043, ss6404694922, ss8226956354, ss8237594473, ss8237594474, ss8315964746, ss8433821733, ss8512049094, ss8623976825, ss8624087144, ss8624425198, ss8662060918, ss8799404773, ss8800005032, ss8800220227, ss8840315230, ss8847494450, ss8847837936, ss8848484986, ss8953479395, ss8979541434, ss8981036615, ss8981836598, ss8981836599, ss8982306058 | NC_000019.9:15990430:C:T | NC_000019.10:15879620:C:T | (self) |
| RCV000211144.13, RCV000211318.11, RCV001510827.13, RCV003977584.1, 99635802, 60608943, 573883702, 1672720, 48033936, 5630, 198962619, 284889978, 10702975169, ss2224611685, ss3028622882, ss3702432955, ss3725714091, ss3821115232, ss6181586799, ss6322041873, ss6398182038, ss6404205566, ss6465265018, ss8069344314, ss8236957552, ss8237672023, ss8306651198, ss8314452463, ss8499258079, ss8612109867, ss8785311404, ss8817445982, ss8852221536, ss8927459668, ss8982058198, ss10046278913 | NC_000019.10:15879620:C:T | NC_000019.10:15879620:C:T | (self) |
| ss3027906, ss3226797, ss4328382, ss6311703, ss44195107, ss65726262, ss66611224, ss67224994, ss67619762, ss69224927, ss70703289, ss71269657, ss74806833, ss75442178, ss79114421, ss83972881, ss84157666, ss86240312, ss105109893, ss105439801, ss121917510, ss137570759, ss153854667, ss159359035, ss159738914, ss160502646, ss171020280, ss173118518, ss244287169, ss410919430 | NT_011295.11:7253232:C:T | NC_000019.10:15879620:C:T | (self) |
Help
Publications tab displays PubMed articles citing the variation as a listing of PMID, Title, Author, Year, Journal, ordered by Year, descending.
202
citations for rs2108622
| PMID | Title | Author | Year | Journal |
|---|---|---|---|---|
| 18250228 | CYP4F2 genetic variant alters required warfarin dose. | Caldwell MD et al. | 2008 | Blood |
| 18535201 | A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. | Cooper GM et al. | 2008 | Blood |
| 18778477 | Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. | Van Ness B et al. | 2008 | BMC medicine |
| 18787519 | A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men. | Fu Z et al. | 2008 | American journal of hypertension |
| 18971550 | Haplotype-based case-control study of the human CYP4F2 gene and essential hypertension in Japanese subjects. | Fu Z et al. | 2008 | Hypertension research |
| 19097922 | A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men. | Fu Z et al. | 2009 | Molecular genetics and metabolism |
| 19207028 | CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. | Borgiani P et al. | 2009 | Pharmacogenomics |
| 19270263 | Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. | Pérez-Andreu V et al. | 2009 | Blood |
| 19297519 | CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. | McDonald MG et al. | 2009 | Molecular pharmacology |
| 19300499 | A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. | Takeuchi F et al. | 2009 | PLoS genetics |
| 19578179 | A genome-wide association study of acenocoumarol maintenance dosage. | Teichert M et al. | 2009 | Human molecular genetics |
| 19741565 | Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. | Zhang JE et al. | 2009 | Pharmacogenetics and genomics |
| 19794411 | Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. | Pautas E et al. | 2010 | Clinical pharmacology and therapeutics |
| 19955245 | Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. | Moyer TP et al. | 2009 | Mayo Clinic proceedings |
| 19957603 | [Association on the haplotypes of CYP4F2 gene and myocardial infarction]. | Huang D et al. | 2009 | Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi |
| 20072124 | Genetic and clinical predictors of warfarin dose requirements in African Americans. | Cavallari LH et al. | 2010 | Clinical pharmacology and therapeutics |
| 20128861 | Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. | Lubitz SA et al. | 2010 | Journal of thrombosis and haemostasis |
| 20130494 | Association of common variants of CYP4A11 and CYP4F2 with stroke in the Han Chinese population. | Ding H et al. | 2010 | Pharmacogenetics and genomics |
| 20149073 | Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. | Pérez-Andreu V et al. | 2010 | Journal of thrombosis and haemostasis |
| 20182420 | Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. | Perini JA et al. | 2010 | Clinical pharmacology and therapeutics |
| 20200517 | A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. | Voora D et al. | 2010 | Clinical pharmacology and therapeutics |
| 20227456 | CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population. | Deng S et al. | 2010 | Progress in neuro-psychopharmacology & biological psychiatry |
| 20377871 | SNP-RFLPing 2: an updated and integrated PCR-RFLP tool for SNP genotyping. | Chang HW et al. | 2010 | BMC bioinformatics |
| 20421126 | A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. | Wells PS et al. | 2010 | Thrombosis research |
| 20435227 | Clinical assessment incorporating a personal genome. | Ashley EA et al. | 2010 | Lancet (London, England) |
| 20442691 | Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. | Sagreiya H et al. | 2010 | Pharmacogenetics and genomics |
| 20462345 | Implementing genotype-guided antithrombotic therapy. | Seip RL et al. | 2010 | Future cardiology |
| 20538623 | Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. | Yang X et al. | 2010 | Genome research |
| 20555338 | Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. | Ross KA et al. | 2010 | Journal of human genetics |
| 20585445 | A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. | Verde Z et al. | 2010 | PloS one |
| 20653676 | CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. | Cen HJ et al. | 2010 | British journal of clinical pharmacology |
| 20833655 | Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. | Cha PC et al. | 2010 | Human molecular genetics |
| 21063236 | Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. | Teichert M et al. | 2011 | Pharmacogenetics and genomics |
| 21084764 | Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. | Singh O et al. | 2011 | Drug metabolism and pharmacokinetics |
| 21110013 | Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. | Geisen C et al. | 2011 | European journal of clinical pharmacology |
| 21127708 | Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. | Kringen MK et al. | 2011 | Journal of biomedicine & biotechnology |
| 21174619 | VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. | Zambon CF et al. | 2011 | Pharmacogenomics |
| 21187935 | Genes involved in the metabolism of poly-unsaturated fatty-acids (PUFA) and risk for Crohn's disease in children & young adults. | Costea I et al. | 2010 | PloS one |
| 21228733 | Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. | Shahin MH et al. | 2011 | Pharmacogenetics and genomics |
| 21320153 | Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. | Botton MR et al. | 2011 | British journal of clinical pharmacology |
| 21326313 | Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. | Choi JR et al. | 2011 | Journal of human genetics |
| 21383771 | Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. | Chan SL et al. | 2012 | The pharmacogenomics journal |
| 21562135 | Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses. | Burmester JK et al. | 2011 | Clinical medicine & research |
| 21562147 | Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. | Zhang X et al. | 2011 | Drug metabolism and disposition |
| 21573225 | Genetic background of patients from a university medical center in Manhattan: implications for personalized medicine. | Tayo BO et al. | 2011 | PloS one |
| 21575037 | Population diversity and the performance of warfarin dosing algorithms. | Suarez-Kurtz G et al. | 2011 | British journal of clinical pharmacology |
| 21625857 | Association of 1347 G/A cytochrome P450 4F2 (CYP4F2) gene variant with hypertension and stroke. | Munshi A et al. | 2012 | Molecular biology reports |
| 21639946 | Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. | Suriapranata IM et al. | 2011 | BMC medical genetics |
| 21729881 | Genome-wide association study identifies common variants associated with circulating vitamin E levels. | Major JM et al. | 2011 | Human molecular genetics |
| 21883387 | Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. | Lacut K et al. | 2012 | British journal of clinical pharmacology |
| 21918509 | Pharmacogenomics: application to the management of cardiovascular disease. | Johnson JA et al. | 2011 | Clinical pharmacology and therapeutics |
| 21921273 | Cardiovascular pharmacogenomics. | Roden DM et al. | 2011 | Circulation research |
| 21923605 | Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. | Cavallari LH et al. | 2011 | Pharmacotherapy |
| 21935354 | Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. | Dewey FE et al. | 2011 | PLoS genetics |
| 22010099 | VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. | Biss TT et al. | 2012 | Blood |
| 22023024 | The pharmacogenetics of the response to warfarin in Chinese. | Lam MP et al. | 2012 | British journal of clinical pharmacology |
| 22114699 | Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. | Gong IY et al. | 2011 | PloS one |
| 22122181 | Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. | Cavallari LH et al. | 2011 | Pharmacotherapy |
| 22130800 | Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. | Moreau C et al. | 2012 | Blood |
| 22135769 | Gene-drug interaction in stroke. | Amici S et al. | 2011 | Stroke research and treatment |
| 22172097 | CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. | Nakamura K et al. | 2012 | Journal of clinical pharmacy and therapeutics |
| 22188360 | Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU. | Scott SA et al. | 2012 | Pharmacogenomics |
| 22192158 | Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. | Liang R et al. | 2012 | Thrombosis research |
| 22329724 | Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. | Ramirez AH et al. | 2012 | Pharmacogenomics |
| 22373437 | Identification of functional genetic variation in exome sequence analysis. | Jaffe A et al. | 2011 | BMC proceedings |
| 22417713 | Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study. | Bejarano-Achache I et al. | 2012 | Clinical therapeutics |
| 22437554 | Genome-wide association study identifies three common variants associated with serologic response to vitamin E supplementation in men. | Major JM et al. | 2012 | The Journal of nutrition |
| 22486182 | Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients. | Smires FZ et al. | 2012 | Journal of clinical pharmacy and therapeutics |
| 22528326 | Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. | Liang R et al. | 2012 | Journal of thrombosis and thrombolysis |
| 22534826 | A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. | Wei M et al. | 2012 | Thrombosis and haemostasis |
| 22549502 | Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. | Lee KE et al. | 2012 | Therapeutic drug monitoring |
| 22629463 | Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. | Rathore SS et al. | 2012 | PloS one |
| 22676192 | Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. | Pavani A et al. | 2012 | Pharmacogenomics |
| 22676711 | Pharmacogenomics of warfarin in populations of African descent. | Suarez-Kurtz G et al. | 2013 | British journal of clinical pharmacology |
| 22754184 | Pharmacogenetic aspects of coumarinic oral anticoagulant therapies. | Rathore SS et al. | 2011 | Indian journal of clinical biochemistry |
| 22833659 | Gender and single nucleotide polymorphisms in MTHFR, BHMT, SPTLC1, CRBP2, CETP, and SCARB1 are significant predictors of plasma homocysteine normalized by RBC folate in healthy adults. | Clifford AJ et al. | 2012 | The Journal of nutrition |
| 22855348 | Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. | Rusdiana T et al. | 2013 | European journal of clinical pharmacology |
| 22871975 | Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction. | Kurnik D et al. | 2012 | Thrombosis and haemostasis |
| 22892446 | Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients. | Hirai K et al. | 2013 | Drug metabolism and pharmacokinetics |
| 22911785 | An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. | Borobia AM et al. | 2012 | PloS one |
| 22952875 | Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. | Jorgensen AL et al. | 2012 | PloS one |
| 22992668 | Pharmacogenomics knowledge for personalized medicine. | Whirl-Carrillo M et al. | 2012 | Clinical pharmacology and therapeutics |
| 23016735 | Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects? | Belozerceva LA et al. | 2012 | The EPMA journal |
| 23061746 | Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. | Özer M et al. | 2013 | Basic & clinical pharmacology & toxicology |
| 23095502 | Imputation reliability on DNA biallelic markers for drug metabolism studies. | Mijatovic V et al. | 2012 | BMC bioinformatics |
| 23104259 | Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. | Ma C et al. | 2012 | International journal of hematology |
| 23132553 | Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. | Danese E et al. | 2012 | Clinical pharmacology and therapeutics |
| 23215885 | Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. | Bress A et al. | 2012 | Pharmacogenomics |
| 23226061 | The role of genetics in pre-eclampsia and potential pharmacogenomic interventions. | Williams PJ et al. | 2012 | Pharmacogenomics and personalized medicine |
| 23237631 | Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. | Carcas AJ et al. | 2012 | Trials |
| 23285254 | Positive selection in the chromosome 16 VKORC1 genomic region has contributed to the variability of anticoagulant response in humans. | Patillon B et al. | 2012 | PloS one |
| 23510058 | Evaluation of the effects of single-nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses. | van Schie RM et al. | 2013 | Journal of thrombosis and haemostasis |
| 23656756 | Single nucleotide polymorphisms in CETP, SLC46A1, SLC19A1, CD36, BCMO1, APOA5, and ABCA1 are significant predictors of plasma HDL in healthy adults. | Clifford AJ et al. | 2013 | Lipids in health and disease |
| 23691226 | Novel associations of VKORC1 variants with higher acenocoumarol requirements. | Anton AI et al. | 2013 | PloS one |
| 23797323 | Pharmacogenomics of anti-platelet and anti-coagulation therapy. | Fisch AS et al. | 2013 | Current cardiology reports |
| 23949431 | Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement. | Tan SL et al. | 2013 | European journal of clinical pharmacology |
| 23990957 | Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model. | Mazzaccara C et al. | 2013 | PloS one |
| 24019055 | Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. | Krishna Kumar D et al. | 2014 | European journal of clinical pharmacology |
| 24029542 | Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects. | Kadian-Dodov DL et al. | 2013 | Vascular medicine (London, England) |
| 24138531 | Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11. | Edson KZ et al. | 2013 | Biochemistry |
| 24330000 | Characterizing variability in warfarin dose requirements in children using modelling and simulation. | Hamberg AK et al. | 2014 | British journal of clinical pharmacology |
| 24340040 | Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. | Preissner SC et al. | 2013 | PloS one |
| 24474498 | VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. | Shaw K et al. | 2014 | Pediatric blood & cancer |
| 24503627 | Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. | Roth JA et al. | 2014 | Clinical pharmacology and therapeutics |
| 24601977 | The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population. | Vear SI et al. | 2014 | British journal of haematology |
| 24759732 | Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials. | Athinarayanan S et al. | 2014 | PloS one |
| 24886380 | CYP4F2 genetic polymorphisms are associated with coronary heart disease in a Chinese population. | Yu C et al. | 2014 | Lipids in health and disease |
| 24896259 | Genome at juncture of early human migration: a systematic analysis of two whole genomes and thirteen exomes from Kuwaiti population subgroup of inferred Saudi Arabian tribe ancestry. | Alsmadi O et al. | 2014 | PloS one |
| 24927344 | CYP4F2 1347 G > A & GGCX 12970 C > G polymorphisms: frequency in north Indians & their effect on dosing of acenocoumarol oral anticoagulant. | Rathore SS et al. | 2014 | The Indian journal of medical research |
| 24944790 | Screening for 392 polymorphisms in 141 pharmacogenes. | Kim JY et al. | 2014 | Biomedical reports |
| 24956252 | Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. | Cerezo-Manchado JJ et al. | 2014 | Pharmacogenomics |
| 25042728 | Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms. | Wypasek E et al. | 2014 | Thrombosis research |
| 25084205 | Methodological issues in the development of a pharmacogenomic algorithm for warfarin dosing: comparison of two regression approaches. | Pavani A et al. | 2014 | Pharmacogenomics |
| 25126975 | A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients. | Chen J et al. | 2014 | PloS one |
| 25148255 | Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses. | Ohara M et al. | 2014 | PloS one |
| 25519826 | An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population. | Krishna Kumar D et al. | 2015 | European journal of clinical pharmacology |
| 25521356 | Genotype and risk of major bleeding during warfarin treatment. | Kawai VK et al. | 2014 | Pharmacogenomics |
| 25594941 | Warfarin dosage response related pharmacogenetics in Chinese population. | Li S et al. | 2015 | PloS one |
| 25734770 | Cytochrome 4A11 Genetic Polymorphisms Increase Susceptibility to Ischemic Stroke and Associate with Atherothrombotic Events After Stroke in Chinese. | Zhang B et al. | 2015 | Genetic testing and molecular biomarkers |
| 25747538 | Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy. | Hirai K et al. | 2015 | Thrombosis research |
| 25848132 | Effects of Pregnane X Receptor Genetic Polymorphisms on Stable Warfarin Doses. | Moon JY et al. | 2015 | Journal of cardiovascular pharmacology and therapeutics |
| 25858232 | Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. | Roth JA et al. | 2015 | Pharmacoepidemiology and drug safety |
| 26024874 | Race influences warfarin dose changes associated with genetic factors. | Limdi NA et al. | 2015 | Blood |
| 26176903 | Interethnic variability of CYP4F2 (V433M) in admixed population of Roma and Hungarians. | Sipeky C et al. | 2015 | Environmental toxicology and pharmacology |
| 26223945 | Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves. | An SH et al. | 2015 | Cardiovascular therapeutics |
| 26249541 | Effects of single nucleotide polymorphisms in c-Myc on stable warfarin doses in patients with cardiac valve replacements. | Lee KE et al. | 2015 | Pharmacogenomics |
| 26257249 | Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. | Chung JE et al. | 2015 | European journal of clinical pharmacology |
| 26355760 | Pharmacogenetic-guided Warfarin Dosing Algorithm in African-Americans. | Alzubiedi S et al. | 2016 | Journal of cardiovascular pharmacology |
| 26444257 | Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. | Chan SL et al. | 2016 | Pharmacogenetics and genomics |
| 26644206 | Effect of gene polymorphims on the warfarin treatment at initial stage. | Liu J et al. | 2017 | The pharmacogenomics journal |
| 26739746 | A multi-factorial analysis of response to warfarin in a UK prospective cohort. | Bourgeois S et al. | 2016 | Genome medicine |
| 26745506 | A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. | Duconge J et al. | 2016 | PloS one |
| 26877068 | Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users. | Shendre A et al. | 2016 | Pharmacotherapy |
| 26959478 | Interaction Between CYP4F2 rs2108622 and CPY4A11 rs9333025 Variants Is Significantly Correlated with Susceptibility to Ischemic Stroke and 20-Hydroxyeicosatetraenoic Acid Level. | Liao D et al. | 2016 | Genetic testing and molecular biomarkers |
| 26977927 | A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. | Tong HY et al. | 2016 | PloS one |
| 26981194 | Complexity of vitamin E metabolism. | Schmölz L et al. | 2016 | World journal of biological chemistry |
| 27061505 | Plasma levels of vitamin K and the risk of ischemic heart disease: a Mendelian randomization study. | Schooling CM et al. | 2016 | Journal of thrombosis and haemostasis |
| 27073641 | Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis. | Sun X et al. | 2016 | Biomedical reports |
| 27262824 | Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients. | Wakamiya T et al. | 2016 | Molecular diagnosis & therapy |
| 27425035 | CYP4F2 affects phenotypic outcome in adrenoleukodystrophy by modulating the clearance of very long-chain fatty acids. | van Engen CE et al. | 2016 | Biochimica et biophysica acta |
| 27488389 | Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese. | Zeng WT et al. | 2016 | European journal of clinical pharmacology |
| 27617219 | Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis. | Zhang J et al. | 2016 | Meta gene |
| 27632229 | Genetic determinants of variability in warfarin response after the dose-titration phase. | Iwuchukwu OF et al. | 2016 | Pharmacogenetics and genomics |
| 27652291 | CYP4F2 (rs2108622) Gene Polymorphism Association with Age-Related Macular Degeneration. | Sakiene R et al. | 2016 | Advances in medicine |
| 28049362 | Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients. | Gaikwad T et al. | 2018 | Clinical and applied thrombosis/hemostasis |
| 28079798 | Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement. | Liu R et al. | 2017 | Medicine |
| 28262345 | Influence of NR3C1 and VDR polymorphisms on stable warfarin dose in patients with mechanical cardiac valves. | Lee KE et al. | 2017 | International journal of cardiology |
| 28401802 | The Impact of Gene Polymorphisms on Anticoagulation Control With Warfarin. | Jiang HH et al. | 2018 | Clinical and applied thrombosis/hemostasis |
| 28550460 | The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients. | Wattanachai N et al. | 2017 | European journal of clinical pharmacology |
| 28592190 | Genetic variants associated with warfarin dosage in Kuwaiti population. | John SE et al. | 2017 | Pharmacogenomics |
| 28604225 | The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy. | Tatarunas V et al. | 2017 | Pharmacogenomics |
| 28620303 | Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response. | Zhang JE et al. | 2017 | Frontiers in pharmacology |
| 28704416 | Genetic variation in the eicosanoid pathway is associated with non-small-cell lung cancer (NSCLC) survival. | Sausville LN et al. | 2017 | PloS one |
| 28806186 | The impact of CYP2C19*2, CYP4F2*3, and clinical factors on platelet aggregation, CYP4F2 enzyme activity, and 20-hydroxyeicosatetraenoic acid concentration in patients treated with dual antiplatelet therapy. | Tatarunas V et al. | 2017 | Blood coagulation & fibrinolysis |
| 29054760 | Polymorphisms of vitamin K-related genes (EPHX1 and VKORC1L1) and stable warfarin doses. | Chung JE et al. | 2018 | Gene |
| 29193749 | Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years. | Borobia AM et al. | 2018 | Clinical and translational science |
| 29201113 | Correlation between Rs2108622 Locus of CYP4F2 Gene Single Nucleotide Polymorphism and Warfarin Dosage in Iranian Cardiovascular Patients. | Khosropanah S et al. | 2017 | Iranian journal of pharmaceutical research |
| 29273767 | The rs2108622 polymorphism is related to the early risk of ischemic stroke in non-valvular atrial fibrillation subjects under oral anticoagulation. | Colàs-Campàs L et al. | 2018 | The pharmacogenomics journal |
| 29426278 | Cytochrome P450 family 4 subfamily F member 2 (CYP4F2) rs1558139, rs2108622 polymorphisms and susceptibility to several cardiovascular and cerebrovascular diseases. | Zhang T et al. | 2018 | BMC cardiovascular disorders |
| 29479633 | Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population. | Ajmi M et al. | 2018 | European journal of clinical pharmacology |
| 29776386 | Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation. | Li J et al. | 2018 | BMC cardiovascular disorders |
| 30409984 | Assessment of coding region variants in Kuwaiti population: implications for medical genetics and population genomics. | John SE et al. | 2018 | Scientific reports |
| 30712247 | Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey. | Kocael A et al. | 2019 | Molecular biology reports |
| 30758238 | Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel. | Langaee T et al. | 2019 | Genetic testing and molecular biomarkers |
| 30932691 | Association Between the CYP4F2 Gene rs1558139 and rs2108622 Polymorphisms and Hypertension: A Meta-Analysis. | Geng H et al. | 2019 | Genetic testing and molecular biomarkers |
| 31019283 | Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests. | Thauvin-Robinet C et al. | 2019 | European journal of human genetics |
| 31103344 | Circulating phylloquinone, inactive Matrix Gla protein and coronary heart disease risk: A two-sample Mendelian Randomization study. | Zwakenberg SR et al. | 2020 | Clinical nutrition (Edinburgh, Scotland) |
| 31105858 | Impact of gene polymorphism on the initiation and maintenance phases of warfarin therapy in Chinese patients undergoing heart valve replacement. | Liu J et al. | 2019 | American journal of translational research |
| 31505768 | Circulating Vitamin E Levels and Risk of Coronary Artery Disease and Myocardial Infarction: A Mendelian Randomization Study. | Wang T et al. | 2019 | Nutrients |
| 31524542 | Correction to: Association Between the CYP4F2 Gene rs1558139 and rs2108622 Polymorphisms and Hypertension: A Meta-Analysis by Geng H, Li B, Wang Y, and Wang L. Genet Test Mol Biomarkers 2019;23:342-347. DOI: 10.1089/gtmb.2018.0202. | 2019 | Genetic testing and molecular biomarkers | |
| 31524544 | Response to Gholami and Mohammad Amoli: Re: Association Between the CYP4F2 Gene rs1558139 and rs2108622 Polymorphisms and Hypertension: A Meta-Analysis by Geng et al.(Genet Test Mol Biomarkers 2019;23:342-347; DOI: 10.1089/gtmb.2018.0202). | Geng H et al. | 2019 | Genetic testing and molecular biomarkers |
| 31524545 | Re: "Association Between the CYP4F2 Gene rs1558139 and rs2108622 Polymorphisms and Hypertension: A Meta-Analysis" by Geng et al. (Genet Test Mol Biomarkers 2019;23:342-347; DOI: 10.1089/gtmb.2018.0202). | Gholami M et al. | 2019 | Genetic testing and molecular biomarkers |
| 31652446 | Identification of novel non-synonymous variants associated with type 2 diabetes-related metabolites in Korean population. | Park TJ et al. | 2019 | Bioscience reports |
| 31854268 | Impact of CYP2C9, VKORC1, ApoE and ABCB1 polymorphisms on stable warfarin dose requirements in elderly Chinese patients. | Li W et al. | 2020 | Pharmacogenomics |
| 32228310 | Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients. | Rojo M et al. | 2020 | Clinical and applied thrombosis/hemostasis |
| 32303955 | Clinically relevant pharmacogenetic markers in Tatars and Balkars. | Abdullaev SP et al. | 2020 | Molecular biology reports |
| 32326111 | Role of Genetic Variations in the Hepatic Handling of Drugs. | Marin JJG et al. | 2020 | International journal of molecular sciences |
| 32327994 | A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study. | Roco A et al. | 2020 | Frontiers in pharmacology |
| 32332930 | Genotype-guided warfarin dosing may benefit patients with mechanical aortic valve replacements: randomized controlled study. | Lee KE et al. | 2020 | Scientific reports |
| 32380173 | Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and the College of American Pathologists. | Pratt VM et al. | 2020 | The Journal of molecular diagnostics |
| 33031748 | A Genome-wide Association Study Discovers 46 Loci of the Human Metabolome in the Hispanic Community Health Study/Study of Latinos. | Feofanova EV et al. | 2020 | American journal of human genetics |
| 33430289 | Combination of Genome-Wide Polymorphisms and Copy Number Variations of Pharmacogenes in Koreans. | Han N et al. | 2021 | Journal of personalized medicine |
| 33437219 | Influence of CYP4F2, ApoE, and CYP2A6 gene polymorphisms on the variability of Warfarin dosage requirements and susceptibility to cardiovascular disease in Jordan. | Al-Eitan LN et al. | 2021 | International journal of medical sciences |
| 33519226 | Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon. | Fernandes MR et al. | 2021 | Pharmacogenomics and personalized medicine |
| 33805706 | SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. | Zubiaur P et al. | 2021 | Journal of personalized medicine |
| 33811620 | Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study. | Sridharan K et al. | 2021 | Pharmacological reports |
| 34302632 | The association study between CYP20A1, CYP4F2, CYP2D6 gene polymorphisms and coronary heart disease risk in the Han population in southern China. | Liang T et al. | 2022 | Genes & genomics |
| 34357562 | Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients. | Hirata TDC et al. | 2021 | Molecular diagnosis & therapy |
| 34429635 | Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population. | He C et al. | 2021 | Pharmacogenomics and personalized medicine |
| 34559488 | Retrospective pharmacogenetic analysis of a pediatric patient under anticoagulant treatment: Clinical case. | Cavieres M et al. | 2021 | Biomedica |
| 34577897 | ABCA1 rs1883025 and CYP4F2 rs2108622 Gene Polymorphism Association with Age-Related Macular Degeneration and Anti-VEGF Treatment. | Mockute R et al. | 2021 | Medicina (Kaunas, Lithuania) |
| 34621706 | Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform. | Kim B et al. | 2021 | Translational and clinical pharmacology |
| 34690761 | Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin. | Villapalos-García G et al. | 2021 | Frontiers in pharmacology |
| 34798807 | Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China. | Li D et al. | 2021 | BMC genomic data |
| 34949935 | Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China. | Wang Y et al. | 2021 | Pharmacogenomics and personalized medicine |
| 34958284 | Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes. | Muyambo S et al. | 2022 | Omics |
| 35040869 | Change in plasma α-tocopherol associations with attenuated pulmonary function decline and with CYP4F2 missense variation. | Xu J et al. | 2022 | The American journal of clinical nutrition |
| 35089958 | Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population. | Goljan E et al. | 2022 | PloS one |
| 36164570 | Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard. | Alshabeeb MA et al. | 2022 | Saudi pharmaceutical journal |
| 36210801 | A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients. | Asiimwe IG et al. | 2022 | Frontiers in pharmacology |
| 36285665 | Diversity of pharmacogenomic variants affecting warfarin metabolism in Sri Lankans. | Ranasinghe P et al. | 2022 | Pharmacogenomics |
| 36335097 | Analysis of clinically relevant variants from ancestrally diverse Asian genomes. | Chan SH et al. | 2022 | Nature communications |
Help
The Flanks tab provides retrieving flanking sequences of a SNP on all molecules that have placements.
Genome context:
Select flank length:
Genomic regions, transcripts, and products
Top▲
Help
NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.
NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.